These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15894755)

  • 1. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?
    Doehner W; Anker SD
    Heart; 2005 Jun; 91(6):707-9. PubMed ID: 15894755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
    Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
    Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Xanthine Oxidase Inhibitors Improve Cardiac Function in Patients With Chronic Heart Failure?
    Sugihara S; Yamamoto K; Hisatome I
    Int Heart J; 2016 Dec; 57(6):661-662. PubMed ID: 27818485
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress.
    George J; Struthers AD
    Vasc Health Risk Manag; 2009; 5(1):265-72. PubMed ID: 19436671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
    Givertz MM; Anstrom KJ; Redfield MM; Deswal A; Haddad H; Butler J; Tang WH; Dunlap ME; LeWinter MM; Mann DL; Felker GM; O'Connor CM; Goldsmith SR; Ofili EO; Saltzberg MT; Margulies KB; Cappola TP; Konstam MA; Semigran MJ; McNulty SE; Lee KL; Shah MR; Hernandez AF;
    Circulation; 2015 May; 131(20):1763-71. PubMed ID: 25986447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allopurinol and endothelial function in heart failure: future or fantasy?
    Landmesser U; Drexler H
    Circulation; 2002 Jul; 106(2):173-5. PubMed ID: 12105153
    [No Abstract]   [Full Text] [Related]  

  • 7. Xanthine oxidase inhibition and heart failure: novel therapeutic strategy for ventricular dysfunction?
    Hajjar RJ; Leopold JA
    Circ Res; 2006 Feb; 98(2):169-71. PubMed ID: 16456108
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.
    Pacher P; Nivorozhkin A; Szabó C
    Pharmacol Rev; 2006 Mar; 58(1):87-114. PubMed ID: 16507884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xanthine oxidase inhibitors: an emerging class of drugs for heart failure.
    Kittleson MM; Hare JM
    Eur Heart J; 2005 Aug; 26(15):1458-60. PubMed ID: 15917281
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacotherapy: Xanthine oxidase inhibition for relief of angina pectoris.
    de Silva R; Fox KM
    Nat Rev Cardiol; 2010 Nov; 7(11):603-4. PubMed ID: 20975655
    [No Abstract]   [Full Text] [Related]  

  • 11. Xanthine oxidase inhibitors the unappreciated treatment for heart failure.
    Ellestad MH
    Cardiovasc Hematol Disord Drug Targets; 2007 Dec; 7(4):291-4. PubMed ID: 18220728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allopurinol improves endothelial dysfunction in chronic heart failure.
    Farquharson CA; Butler R; Hill A; Belch JJ; Struthers AD
    Circulation; 2002 Jul; 106(2):221-6. PubMed ID: 12105162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure.
    Ekelund UE; Harrison RW; Shokek O; Thakkar RN; Tunin RS; Senzaki H; Kass DA; Marbán E; Hare JM
    Circ Res; 1999 Sep; 85(5):437-45. PubMed ID: 10473673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure.
    Gavin AD; Struthers AD
    Heart; 2005 Jun; 91(6):749-53. PubMed ID: 15894768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Xanthine Oxidase Inhibitors in Patients with History of Stroke: A Systematic Review.
    Britnell SR; Chillari KA; Brown JN
    Curr Vasc Pharmacol; 2018; 16(6):583-588. PubMed ID: 28933307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allopurinol as a therapeutic option in cardiovascular disease.
    Okafor ON; Farrington K; Gorog DA
    Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy.
    Duncan JG; Ravi R; Stull LB; Murphy AM
    Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1512-8. PubMed ID: 15863459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uric acid in chronic heart failure.
    Doehner W; Anker SD
    Semin Nephrol; 2005 Jan; 25(1):61-6. PubMed ID: 15660337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allopurinol and endothelial function: A systematic review with meta-analysis of randomized controlled trials.
    Alem MM
    Cardiovasc Ther; 2018 Aug; 36(4):e12432. PubMed ID: 29673103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?
    Reyes AJ; Leary WP
    Cardiovasc Drugs Ther; 2005 Oct; 19(5):311-3. PubMed ID: 16382292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.